BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib in Achondroplasia, Meeting Primary and Key Secondary Endpoints

summarizeSummary

BridgeBio Pharma reported positive Phase 3 topline results for oral infigratinib in achondroplasia, meeting primary and key secondary endpoints, and plans regulatory submissions in H2 2026.

check_boxKey Events

• Positive Phase 3 Topline Results

  Oral infigratinib successfully met the primary endpoint of change from baseline in annualized height velocity (AHV) at Week 52 (p<0.0001) in the PROPEL 3 study for achondroplasia.

• First Statistically Significant Improvement in Body Proportionality

  The study achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, specifically in children younger than 8 years old (p<0.05).

• Well-Tolerated Safety Profile

  Oral infigratinib was well-tolerated with no discontinuations or serious adverse events related to the study drug, and no adverse events associated with FGFR1 or FGFR2 inhibition.

• Regulatory Submissions Planned

  BridgeBio plans to submit New Drug Application (NDA) and Marketing Authorization Application (MAA) for infigratinib in the second half of 2026, leveraging its Breakthrough Therapy Designation.

auto_awesomeAnalysis

BridgeBio Pharma announced highly positive Phase 3 topline results for oral infigratinib in children with achondroplasia. The PROPEL 3 study successfully met its primary endpoint of change from baseline in annualized height velocity (AHV) and, notably, achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia for children younger than 8 years old. The drug was well-tolerated with no discontinuations or serious adverse events related to the study drug. These strong results, coupled with the drug's Breakthrough Therapy Designation, pave the way for New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in the second half of 2026. The company also plans to accelerate development for hypochondroplasia, indicating confidence in the drug's mechanism and potential across related conditions. This represents a significant advancement for patients and a major positive catalyst for BridgeBio's pipeline.